Clinical Trial Detail

NCT ID NCT02032810
Title Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

melanoma

Therapies

Panobinostat

Ipilimumab

Age Groups: adult

No variant requirements are available.